Grant FundingRecent grant from the Gates Foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.
Phase 3 Trial ApprovalThe FDA's agreement on just a 12-week treatment period for sildenafil cream's Phase 3 trial is significant, as it deviates from the standard 24 weeks of blinded treatment, indicating potential for quicker market entry.
Strategic PartnershipsBayer may exercise its commercial option for Ovaprene after Phase 3 readout, potentially bringing in an additional $20M, showcasing strong strategic interest in the program.